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Abstract
Multifocal, multicentric, and bilateral breast tumours are either benign, 
precursor lesions or malignant neoplasms.A multidisciplinary review of these 
entities can offer clinicians a practical guidance for diagnostic and treatment 
procedures. Multiple synchronous (multifocal or multicentric) ipsilateral breast 
cancers (MSIBC) with heterogeneous histopathology require particular atten-
tion, since MSIBC tends toward more aggressive biology and higher rates of nodal 
positivity. Being independent of laterality, domination of the invasive carcinoma 
was observed in the bilateral and multifocal disease type. The TNM staging system 
for breast cancer does not include multifocality and multiplicity. Only the tumour 
with the largest diameter is considered for the pT category, neglecting the second-
ary foci which can make the treatment decision more difficult. MSIBC has a similar 
prognosis to unifocal cancers, but sometimes they might be negative prognostic 
parameters. Likewise, in comparison with unifocal breast cancer, MSIBC presents 
a different genetic pathway.
Keywords: Multiple synchronous tumour, multifocal, multicentric, bilateral,  
breast cancer
1. Introduction
The multifocal, multicentric, and bilateral aspects of breast cancer (BC) are 
the eternal dilemma in the scientific literature. Breast cancer is the most com-
mon tumour disease and the second leading cause of death in American women, 
with 268,600 new cases and 41,760 deaths in 2019 [1]. The second most com-
mon malignancy in patients with breast cancer is contralateral breast cancer [2]. 
Presence of another focus of breast cancer, far away from the dominant mass, was 
described as early as 1920 by Cheatle [3]. The appearance of such non-dominant 
lesions in multiple ducts of a single quadrant (multifocal), or in two or more 
quadrants (multicentric) was further elaborated in 1957 by Qualheim and Gall [4]. 
Multifocal/multicentric (MF/MC) breast cancer is occurring frequently, however, 
its genesis is not fully understood  [5].
Previous studies evaluated histological and immunohistochemical character-
istics [6, 7], revealing that most multicentric breast cancers share similar features 
in terms of histology and immunohistochemistry, suggesting that early-stage 
synchronous tumours develop from one breast cancer  [6]. The heterogeneity of 
the focus of multiple cancers [8] is understudied in the literature, with a number of 
studies which have evaluated histological and immunohistochemical characteristics 
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of tumour foci in multiple cancers arriving at contradictory results and different 
conclusions  [7, 9].
Multiple synchronous ipsilateral breast cancer (MSIBC) with heterogeneous 
histopathology is a controversial condition in a clinical context, which has been 
discussed and studied extensively in the literature, but lacking international con-
sensus on itsdefinition and clinical treatment options. Current incidence of MSIBC 
is unknown, but, owing to improved sensitivity of medical imaging methods 
and the use of magnetic resonance imaging (MRI) for BC screening and staging, 
is showing increased occurrence. This heterogeneous disease requires special 
attention during treatment, given the fact that MSIBC is a much more aggressive 
condition which produces metastases in lymph nodes more frequently  [10].
Based on current therapies for breast cancer, the treatment of this heterogeneous 
disease calls for joint decision making in a multidisciplinary team and in collabora-
tion with an oncology council, where the pathologist, working with the other mem-
bers of the team, influences the new concept of individual approach to treatment of 
MC/MF breast cancer patients with their data and explanations obtained through 
testing. A new rigorous view on genetic patterns of heterogeneity in each individual 
focus would present a more specific approach to treating MSIBC [11].
2.  Terminology and classification of multifocal, multicentric, and 
bilateral breast cancers
Multiple synchronous tumour foci in one breast are referred to as multifocal 
and multicentric, but without a consensus on terminology [12]. MF/MC cancer 
may occur due to intramammary proliferation of a single primary BC or multiple 
synchronous, independent primary breast cancers [5, 13]. Recently, the definition 
of multifocal cancer was changed. Previous definition of multiple synchronous 
lesions of breast cancer stated that these could be either MF or MC, depending on 
where the lesion was located (in the same or different quadrants). The use of breast 
quadrants to define and classify cancers is now considered inappropriate, since 
quadrants are not part of convention which correspond to the breast anatomy [14]. 
Pathologists define multiple simultaneous primary lesions when there are two or 
more tumour foci without malignant tissue between them [15].
Multifocality is usually determined microscopically, when a greater number 
of morphological cancer development centres are present, which is the same 
micromorphological unit or lobe in the breast. Radiologists do not have a more 
precise definition, but tumours are usually considered multifocal when the distance 
between the tumour masses is less than or equal to 5 cm, and multicentric when this 
distance is greater than 5 cm (Figure 1) [16, 17]. Given that a standardised defini-
tion is not established, multifocal and multicentric breast cancers are often grouped 
together as multifocal/multicentric breast cancers [18]. In histological terms, BC is 
defined as multiple cancer when it consists of more than one clearly distinguish-
able tumour foci which are separated by normal and benign breast tissue or ductal 
carcinoma in situ (DCIS) [19].
Various time intervals are used to define bilateral synchronous breast cancer 
(BSBC). In 1921, Kilgore defined BSBC as breast cancer where both tumours are 
diagnosed simultaneously [20]. Since 1921, various time intervals were introduced, 
ranging from one to five years [21]. A broadly accepted definition of BSBC is the 
one given by Hartman and co-authors in 2007 as a tumour diagnosed within 90 days 
after the initial mass has occurred. Although the reported time intervals vary, 
bilateral BCs are considered to be synchronous when contralateral BC is diagnosed 
within a period of three months, and as metachronous bilateral cancers (BMBC) 
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when diagnosed more than three months after the first diagnosis [22]. Limit values 
used in the literature to differentiate between BSBC and BMBC range from 1 to 
12 months [23]. Before a bilateral breast cancer diagnosis is confirmed, metastatic 
contralateral breast cancer has to be ruled out [24].
The definitions of multifocality, multicentricity, and bilaterality refer primar-
ily to the two most common types of breast cancer (ductal and lobular), but can 
also refer to certain lesions which occur less frequently in the breast. In terms of 
multifocality, between 10 and 20% of tubular carcinomas may present as multifo-
cal [25, 26], and the identical frequency of multifocality is observed in cribriform 
Figure 1. 
Images from mammograms of ILC from three different patients: (A) stellate tumour shadow of unifocal ILC 
from the 58 years old patient; (B) multicentric (bicentric) ILC from the 53 years old patient; (C) bilateral 
synchronous ILC from the 32 years old patient. In reference [16](the figure was taken from article; permission 
obtained from the copyright owner).
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cancers [27, 28]. A thorough sampling of large areas with high DCIS grade should 
be performed in order not to miss the foci of the carcinoma microinvasions (or 
invasions). Some reports suggested that when a microinvasive carcinoma occurs, 
it is likely to be multifocal [29].
Certain benign lesions, such as papilloma, are rarely multiple in nature 
(Figure 2). Breast lesions which often present as bilateral are DCIS [30], Paget’s 
disease of the nipple, radial scars and complex sclerosinglesions, gynecomastia, 
Burkitt lymphoma [31], while bilateral breast cancer also frequently occurs in 
patients with Cowden syndrome and heterozygous ATM mutation carriers (ataxia 
telangiectasia), as a result of submitting patients suffering from Louis–Bar syndrome 
to radiotherapy [31–33]. Other types of potentially bilateral-onset breast lesions 
are atypical ductal hyperplasia [31], phyllodes tumour [32, 34], myofibroblastoma 
[33], desmoidfibromatosis [35], male breast cancer [36], angiosarcoma [37, 38], 
liposarcoma [31], lymphoma (about 10% of the cases), pseudoangiomatous stromal 
Figure 2. 
Multiple breast papillomas in multilocular cyst of the 52 years old patient. (A) Macroscopic appearance;  
(B) microscopic appearance of breast papilloma (HE x 100)(image was taken from author’s own lab).
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hyperplasia [39], ductal adenoma in patients with Carney syndrome [40]. There 
are also lesions with unidentified bilaterality, some of which are ALK-negative 
anaplastic large cell lymphoma [31], mucosa associated lymphoid tissue lym-
phoma [41] and granular cell tumour [42]. Most patients with diffuse large B-cell 
lymphoma develop a unilateral condition, but there is a risk of relapse in the 
contralateral breast [43].
3. Epidemiology and risk factors
Based on data from the literature, there is no consensus on the factors relating 
to the development of multicentric carcinomas [44]. MF/MC BC incidence ranges 
from 6 to 77% [14]. Bilateral breast cancers are responsible for 2 to 6% of all breast 
carcinomas [22]. Earlier studies have shown that one of the most important risk 
factors for MCBC is if the first occurrence is an invasive lobular carcinoma (ILC) 
[45]. Low-grade invasive ductal carcinomas (IDC) are not linked with the number 
of tumour masses in the contralateral breast. All of these observations contradict 
the fact that ILC is more common among patients with bilateral and multifocal BC 
solely due to slower growth rates [46].
There are no differences when it comes to patient age, tumour stage, or the 
presence of multifocal, multicentric, and bilateral ILCs [47]. Contralateral tumour 
incidence, in particular synchronous ILCs, is in the 5 to 19% range, which is more 
than invasive ductal carcinoma of no special type [45, 48, 49]. BSBC is a rare entity 
with an incidence between 1 and 3%. Surprisingly, there has not been an increase in 
the BSBC incidence since 1980. A lower incidence of metachronous bilateral breast 
cancer was observed, likely due to the introduction of systemic adjuvant therapy. 
In the study on incidence of bilateral breast cancers in Sweden, conducted by 
Hartman and co-authors reported that the incidence of BSBC was approximately 
100 times greater than what can be explained as coincidence or a cumulative effect 
of exogenous carcinogens [22],
Women with MF/MC breast cancers are often of younger age at the time of 
diagnosis and with positive oestrogen (ER) receptors expression than women with 
a unifocal condition [50]. Patients with MF/MC tumours are prevalently premeno-
pausal and with a lower body mass index [51]. Women already suffering from BC 
are at two to six times greater risk of developing contralateral BC compared to the 
risk of other women developing their first primary BC, with the risk being inversely 
proportional to their age at the time of initial diagnosis [45, 52]. Average time 
between the diagnosis of the first BC and metachronous contralateral breast cancer 
varies from 3.9 to 7.7 years [22, 52].
Histological subtype of invasive carcinoma did not prove to be a predictive 
multicentricity factor, particularly in ILC subtypes [16, 47]. Earlier studies suggest 
that ILCs are much more prone to multicentric growth; but when lobular carcinoma 
in situ (LCIS) is excluded, multicentricity is not that common [44, 53]. When 
compared to IDCs, ILCs are ER and progesterone (PR) positive to a larger extent, 
but show lower HER2 positivity with the exception of pleomorphic lobular carci-
noma [31]. Women diagnosed with MF/MC BC proportionally more frequently 
have positive ER receptors and lower prevalence of triple-negative tumour masses. 
Numerous studies documented significantly higher positivity levels of ER receptors 
among the BRCA2 mutation carriers in comparison to BRCA1 mutation carriers. 
Therefore, it is highly unlikely that ER signalisation leads to MF/MC disease [54]. 
An extensive meta-analysis found no connection between the ER status and spo-
radic MF/MC breast cancers, suggesting that the ER status does not play a part in 
the specific development of MF/MC disease [55]. The risk of other contralateral 
Breast Cancer
6
primary breast cancers varies depending on the status of hormone receptors of the 
first tumour, age, race, and/or ethnic origin [56].
A certain number of earlier studies discovered a strong correlation with the 
lobular histology in the first primary breast carcinoma and the occurrence of 
bilateral breast cancer [57]. Women with primary breast cancer who have posi-
tive hormone receptors show twice the risk of developing contralateral BC, while 
women who have cancers with negative hormone receptors are at almost four times 
higher risk as compared to general population with regard to age and race. Women 
with primary tumours who have negative hormone receptors more frequently 
develop secondary tumours which have negative hormone receptors, especially if 
the initial diagnosis is confirmed before the age of thirty [56].
Women who have next of kin with BC are at 50% higher relative risk of devel-
oping bilateral breast cancer than women without family history of this condition 
[22]. When compared to non-carriers, women with BRCA1 mutations are at 4.5 
times greater risk and with BRCA2 mutations at 3.4 times greater risk of bilateral 
breast cancer [58]. On the other hand, carriers of similar ATM gene variants 
have a lower risk of developing contralateral breast cancer [59]. Family history 
of breast carcinoma, younger age at the time of initial diagnosis, or mutation of 
BRCA1 and BRCA2 genes are linked to a higher risk of developing contralateral 
tumours, placing them in the higher risk group [45]. Higher prevalence of mul-
tifocality/multicentricity than expected occurs in women diagnosed with cancer 
who are BRCA2 mutation carriers [50].
4. Radiodiagnostics
Mammography and ultrasound are complementary methods for evaluating the 
size, spread, and the presence of multifocality in BC (Figure 1) [16, 31]. However, 
not all MF/MC cases will necessarily be found using these imaging modalities [60]. 
Radiologic BC characteristics can vary significantly. These differences often depend 
on the tumour grade and histological subtype. Therefore, variations in the radio-
logic presentation can sometimes predict the differences in the morphology and 
biology of the tumour. ILC often invades normal tissue without causing desmoplas-
tic stromal response which is usually found in IDC. For this reason, ILC density is 
often similar to the surrounding normal fibrous and glandular tissue of the breast, 
which makes it inconspicuous in mammographic screening [61, 62], particularly 
since non-desmoplastic ILC produces metastases in axillary lymph nodes more 
frequently [63].
Due to the limited use of mammography in diagnosing ILC and the risks of 
obtaining false negative results, other methods such as sonography and MRI are 
used to assess the tumour dissemination [64]. Magnetic resonance imaging is more 
useful for diagnosing ILC, in particular multifocal lesions, although this imaging 
procedure may produce false positive results or overestimate the tumour stage 
[65, 66]. Recent literature on the role of imaging modalities in the BSBC diagnosis 
suggests that family history of BC, multifocal BC, or the presence of an ILC should 
serve as recommendations to perform an MRI with the purpose of eliminating 
contralateral malignancy [67].
5. Pathology report
In recent decades, pathohistology has made a huge step forward from the 
typical traditional documentation to the ability to modify the histochemical and 
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immunohistochemical methods [68], which has shed new light on some patho-
histological parameters and consequently led to a new approach when it comes to 
recognising the criteria for classifying and grading tumours. Tot et al. support that 
there can be two different types of multifocal invasive carcinoma: one with multiple 
individual invasive foci which develop from in-situ lesions in different parts of the 
same lobe either at the same or at a different time, and one where individual foci 
are in-transit metastases of the primary focus and are not connected to the in-situ 
component [69].
When compared to unilateral BC, bilateral breast cancer is associated with 
significantly lower rate of the ductal type, with a higher histologic grade, HER2 
positivity and metastases in lymph nodes, without differences relating to age, race, 
ER and PR status, or pathologic stage of the tumour disease (Figures 3 and 4).  
Synchronous breast cancer is associated with a higher rate of consistency with 
the ER, PR, and HER2 statuses (Figure 4) as compared to metachronous bilateral 
breast cancer, but without any difference regarding the histologic type or grade 
[70]. A high-grade malignancy and multifocal contralateral breast disease are 
inversely proportional [46], which is why patients with BSBC often develop slow-
growing and low-grade carcinomas [71].
Greater size of the tumour masses and a larger number of the lymph nodes 
affected are also linked with multifocal carcinoma, both in unilateral and bilateral 
Figure 3. 
Macroscopic appearance of BSBC from the 36 years old patient in stage IIIA and IIB: (A) mastectomies of both 
breasts with associated axillary adipose tissue; (B) macroscopic examination of the tumour infiltration zone by 
transverse serial sections; (C) foci of the largest tumour infiltration zones and their distance from the resection 
margins. (image was taken from author’s own lab).
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breast cancers [46]. In unilateral BC patients with a multifocal disease, 40% present 
with tumour foci that have different histopathology [5, 13, 72]. Studies analysing 
clonal origin of the tumour focus in multifocal BC show that at least 50 to 70% of 
cases with different foci are genetically related [73–75], arguing that most multifo-
cal breast carcinomas in patients with unilateral BC originated from the same 
precursor cell, therefore being an intramammary spread of metastases or an in-situ 
carcinoma with numerous invasive foci [14, 73].
Some studies revealed that multiple synchronous ipsilateral breast cancer 
(MSIBC) correlates with the known risk factors, suggesting aggressive biology, such 
as younger age of patients, higher grade, hormone receptor status, HER2 status, 
lymphovascular invasion and node involvement [76, 77]. Other factors can also 
play a part, such as the loss of E-cadherins, causing a loss of cell-to-cell adhesion 
and contributing to metastatic potential. A recent study demonstrated that MSIBC 
had a significant downregulation of E-cadherine expression as opposed to unifocal 
lesions [78].
While desmoplastic stromal response is not associated with higher frequency 
of metastases in axillary lymph nodes [63], there is a positive correlation between 
the presence of metastases in axillary lymph nodes and the number of tumour foci 
[77]. In multiple carcinomas, between 3 and 7% of cases can present with differ-
ent histologic tumour types and/or histologic tumour grades (intratumor hetero-
geneity) [19, 77]. Using androgen receptor tests, it was discovered that some DCIS 
and LCIS develop from different cell clones [79]. If we assume that pure DCIS 
obtains its phenotypic diversity from different cell clones or from accumulated 
genetic alterations of a single clone, followed by the progression of the dominant 
clones to invasive carcinomas, it is possible that these represent different pheno-
types in multifocal/multicentric BC with a heterogeneous DCIS component [5].
If the multifocal/multicentricBC in question develops as a consequence of 
lymphovascular invasion, a higher risk of further metastases is probable. Higher 
frequencies of lymph node involvement and higher relapse rates in MF/MC BC 
than in other unifocal BCs support the idea that they can occur as a result of 
Figure 4. 
Microscopic appearance of BSBC from the 36 years old patient in stage IIIA and IIB. Strong membranous 
expression of HER2 in invasive and “in situ” component of classical subtype of ILC (LSAB x 200). (image was 
taken from author’s own lab).
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lymphovascular invasion, although a high incidence of metastases in lymph 
nodes in MF/MC breast carcinomas is also associated with larger tumours [80, 
81]. When the tumour (T) stage is determined with the diameter of the largest 
lesion, multifocality and multicentricity can act as independent predictors of 
axillary lymph node involvement.
6. Heterogeneity of tumour foci
Heterogeneity is a well-known trait of malignancies. It can be observed in 
individual tumours or among primary BCs and synchronous metastases in lymph 
nodes. This should be particularly emphasised in the case of MSIBC with different 
biology and positive lymph nodes in the diagnosis. The status of axillary lymph 
nodes is the most important individual prognostic factor for BC patients; an accu-
rate histological characterisation of nodal metastases can help clinicians select the 
most appropriate .treatment [11].
Studies suggest that the tumour foci in MF and MC carcinomas may manifest 
clonal and behavioural heterogeneity [76], irrespective of the distance between 
the lesions [7], that ipsilateral foci usually have identical clonality while bilateral 
breast cancers vary [82], and that 25% of MC carcinomas is polyclonal [83]. The 
studyof Nortonand co-authors focusing on multifocal ILCs, numerous genetic 
copies between the foci are consistent to a high degree, suggesting clonal connec-
tion between the foci on the one side, while genetic heterogeneity was observed 
between the foci in patients on the other side [84]. Phenotypic differences are more 
common in foci (Figure 5) that are homogeneous in terms of tumour type and 
grade [76]. Actually, all tumour foci are considered to have the same phenotype, 
although genetic or phenotypic alterations may occur during the progression of the 
tumour [5].
Figure 5. 
Phenotypic differences in ER expression (positive nuclear staining on the right side and negative nuclear staining 
on the left side of tumour focus) may indicate clonal and behavioural heterogeneity of LCIS (LSAB x 200). 
(image was taken from author’s own lab).
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7. Molecular and genetic testing
It is not clear whether multifocal/multicentric BCs with different phenotypes 
are of independent origin due to the fact that phenotypic changes may occur 
during the tumour progression and dissemination [85]. A few studies, using 
various molecular methods, showed that bilateral breast cancers are most likely 
not genetically identical [86, 87]. While the presence of a different phenotype is a 
clear indicator of separate synchronous primary tumours, over 70% of invasive BCs 
classified as IDC have identical morphology, meaning that the tumours are clonally 
related. Using targeted gene sequencing in patients with multiple invasive ductal 
carcinomas of the same grade and hormone receptor status, it was determined that 
one third of the cases shows identical mutation profile, one third shares mutations 
with individual mutations in different foci suggesting identical clonal origin, and 
one third exhibits no common mutations. Despite common mutations not being 
present, common changes in copies among the lesions were found, which requires 
more detailed examinations with methods such as sequencing the entire genome, 
which would reveal common subclones with a clonal distinction in a larger number 
of cases [73].
The 21 gene recurrence score assay is a commercially available prognostic and 
predictive test that measures gene expression levels (16 cancer-related and 5 refer-
ence genes) using RT-PCR. The test generates a numeric RS on a scale of 0 to 100 
to predict a ten-year risk of a distant metastasis as well as the benefit of chemo-
therapy in patients with an early-stage ER positive, HER2 negative breast cancer. 
This RS divides the patients into three risk categories: low (RS < 18), medium 
(RS 18 to 30), and high (RS ≥ 31). Adjuvant chemotherapy is added to endocrine 
therapy in patients with high RS; it is estimated that the benefit is low enough to 
outweigh the consequences in low RS patients [88]. The importance of genome 
testing for classification by risk category was recognised in the eighth edition of 
the AJCC Cancer Staging Manual [89], which integrates RC into BC staging. This 
study examines the consistency of RS in multiple synchronous ipsilateral BCs of 
similar histology [90].
Tsuda and Hirohashi [91]. investigated the loss of heterozygosity at 16q chromo-
some in multiple breast cancers and have decided to define multicentric carcinomas 
as those which are not related through the DCIS component and are not showing 
satellite nodules and can appear independently. On the other hand, Teixera et al 
[82], using cytogenetic analyses, concluded that the dominant origin of multiple 
BCs is intramammary spread from a single primary tumour, despite the fact that 
some cases develop as unrelated pathogenetic processes. Recently, Brommesson and 
co-authors compared genome similarities between synchronous multiple invasive 
breast cancers by means of a comparative microarray-based genome hybridisation 
and discovered that 5 out of 10 unilateral tumour pairs showed similar genome 
profiles, suggesting that some synchronous unilateral multiple tumours may have a 
common origin, while other develop independently [74].
8. Staging of multifocal/MulticentricTumours
Tumour classification as unifocal, MF, or MC is determined in accordance 
with the pathology reports. The size of the tumour is obtained from the pathol-
ogy reports. In patients with MF/MC tumours, T stage is determined using two 
methods: diameter of the largest tumour focus (Tmax) and by adding up the largest 
diameters of all tumour foci that are present in the pathological sample (Tsum) [51]. 
AJCC TNM classification defines tumour size as a measure of the largest individual 
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focus of MSIBC [92]. BSBC should be classified independently to permit separation 
of cases by histological type. (Figures 3 and 4). Some authors support the hypoth-
esis that MSIBCs can be best described as summarised dimensions which reclassify 
tumours to higher stages [93].
According to the College of American Pathologists’ recommendations, when 
multiple synchronous ipsilateral invasive cancers of the same histology are present, 
the largest invasive carcinoma is used for classification and receptor evaluation 
[94]. The largest tumour focus is ranked as index or first-rank tumour, and other 
foci as second to n-rank of additional foci by descending diameter size. The number 
of lymph nodes affected with macrometastases (larger than 2 mm) or micrometas-
tases (with a diameter between 2 and 0.2 mm) is also reported, as well as the total 
number of lymph nodes analysed [8]. When the T stage is determined based on the 
diameter of the largest lesion, multifocality and multicentricity are an independent 
predictor of axillary lymph node involvement. However, redetermining the T stage 
based on the sum of diameters of all foci compensates for their difference, leaving 
the proportion of lymph node metastases between the MC/MF and UF tumours 
equal [93]. These findings suggest that the increase in the lymph node involvement 
(or any other relation with unfavourable outcomes) is not a consequence of the 
common nature of the MC and MF tumours, but rather the result of underestimat-
ing the spread of the disease using current staging systems [95].
Some investigationssuggest that the sum of the largest diameters is actually 
greater than the overall size of the tumour mass and that a better criterion for 
assessing the tendency of metastasis formation is the total volume and surface area 
of the tumour [81]. After reclassifying the tumours according to this model, MF/
MC tumours still show increased level of lymph node involvement, suggesting 
that the difference is not the result of the lower stage, but rather the basically more 
aggressive tumour biology [95].
9. Therapeutic modalities and prognosis
Breast-conserving therapy is now an established alternative to radical mastec-
tomy. When it comes to tumours with more than one lesion, suggested treatments 
are changing at the moment. Many authors continue to support breast-conserving 
surgery for MC/MF tumours [96]. Furthermore, when breast-conserving surgery is 
proposed as a treatment option for patients who carry BRCA2 mutations and have 
ER positive receptor status, the surgeons should bear in mind the increased inci-
dence of multifocality and plan the surgical procedure accordingly, ensure that the 
complete excision is performed in one procedure, as well as minimise the conse-
quences related to repeated surgery due to marginal involvement [50]. Oncoplastic 
surgery enables a more precise resection of the tumour mass and free resection 
margin as compared to standard quadrantectomy or lumpectomy [97].
Considering that the effect of partial breast radiation therapy is limited to the 
index quadrant, it is of paramount importance that patients with low risk of occult 
microscopic disease in the remaining breast tissue are selected, meaning that local 
control is not less important than whole-breast radiation [11]. It has been proven 
that whole-breast radiation after a breast-conserving surgery is more efficient 
against microscopic foci of BC, which is demonstrated by the fact that leaving it out 
increases local recurrence rate to 39.2% [98]. Patients under 45 who have BC and 
were treated with post-lumpectomy tangential field radiotherapy are at higher risk 
of developing contralateral breast cancer, in particular women with family history 
of BC [52, 99]. Adjuvant chemotherapy is also associated with reduced incidence 
(up to 20%) of contralateral breast cancer in women under 50, but not in female 
Breast Cancer
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patients of and above this age [100]. Moreover, chemotherapy is also related with 
a lower risk of contralateral breast cancer for a period of up to 10 years after the 
initial BC diagnosis [101].
It was reported that adjuvant systemic hormone ER positive therapy reduces 
the incidence of contralateral breast cancer by 39 to 55%, depending on the 
menopausal status [100], which is why detecting limit values for the ER receptor 
positivity is important [102]. The analysis of the study results revealed that adjuvant 
chemotherapy is not effective in patients with RS < 25 and above fifty years of age. 
However, women under 50 with BC who have RS in the medium range between 16 
and 25 can still derive some benefit from chemotherapy [103].
Certain data supports the claim that multifocality/multicentricity is not an 
independent prognostic factor for BC. Although it is suggested that MF/MC can 
predict the outcome, it is a fact that the size of the tumour bears greater significance 
in these patients, rather than the presence of multifocality/multicentricity itself 
[50]. There is controversy in the literature relating to MF/MC prognosis. The rate 
of locoregional recurrence has increased in some studies [104], while others found 
no differences [95]. A 2.75 times higher risk of cancer-related death was reported 
in patients with MF breast cancer, irrespective of the molecular subtype [19]. In an 
extensive retrospective study, Weissenbacher et al. reported a lower median global 
survival (OS) in MF/MC patients as compared to unifocal tumours [104]. One 
earlier study showed that MC disease is related to higher local recurrence rates, but 
not MF disease (37 and 17% respectively) [105].
Histologic grade is a well-known prognostic factor for BC, with numerous studies 
demonstrating a strong connection with survival rates [31, 106]. The size of the 
tumour has been identified long ago as an independent indicator of lower global 
survival [107]. Two studies monitored the relation between different methods for T 
staging and survival. It was discovered that MF and MC tumours larger than 2 cm 
are accompanied by lower global survival when compared with unifocal carcinoma, 
but this difference vanishes if the sum of the tumour diameters is used in staging 
[93]. In patients with MF/MC disease, calculating the sum of diameters of multiple 
foci does not add any prognostic information apart from the conventionally deter-
mined T stage on the basis of the largest diameter of the largest focus [108]. A more 
intensive systemic chemotherapy could potentially mask an accurate prognosis 
which is determined by measuring the size of the tumour. The prognosis for patients 
with MF/MC tumours is similar to that for patients with unifocal tumours. In higher 
stages, the presence of lymph node positivity and distant metastases provides more 
significant prognostic information, while the T-stage effect on the prognosis is of 
little importance [51]. Most studies found increased frequency of metastases in 
multiple carcinomas when compared to unifocal carcinomas [77, 104], explaining 
the unfavourable outcome in MSIBC patients [109].
It is difficult to assess the prognosis of bilateral breast cancer, because the 
outcome may not be unevenly ascribed to either the first or the second carcinoma. 
The survival of BSBC patients seems to depend on tumours with poorer histological 
characteristics [110]. Women over the age of 50 with synchronous bilateral carci-
noma or women who develop contralateral breast cancer within 5 years are at two- 
and four-times higher risk, respectively, of dying from cancer than women with 
unilateral carcinoma. The prognosis for women with bilateral breast cancer that was 
diagnosed after 10 years from the initial carcinoma is similar to that for women with 
unilateral BC [22]. There is no significant difference in survival for patients with 
bilateral BC compared to patients with unilateral tumours. However, synchronous 
tumours are accompanied by lower survival compared to metachronous tumours 
[111]. Conversely, global survival is not different in patients with bilateral BC and 
those with unilateral BC [112, 113].
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There is a significantly higher risk of distant metastases being present in bilat-
eral BCs [114]. Bilateral BC is associated with lower grade of the disease, patients 
show an absence of distant metastases prior to developing contralateral breast 
cancer; more importantly, no difference in the disease-specific survival (DSS) was 
noticed among patients with bilateral BC and unilateral BC. Bilateral BC is associ-
ated with shorter relapse-free survival (RFS), but similar DSS when compared to 
unilateral BC. Furthermore, BSBC is associated with favourable RFS, but has similar 
DSS when compared to BMBC with respect to other clinicopathologic parameters in 
patients with bilateral BC [70].
10. Limitations and future guidelines
The incidence of MF/MC breast cancer varies between 6 and 7%, depending 
on somewhat arbitrary definition of the MF/MC imaging method sensitivity and 
biopsy performed by the pathologist. The TNM stage does not include multifocality 
in the tumour classification [51]. As further progress is made in the pre-operative 
diagnostics, the number of identified MF and MC tumour is increasing [115]. and 
consequently better manuals are required for treating them [95], as well as stan-
dardised immunohistochemical procedures which would reduce the subjectivity 
and intralaboratory variations in the interpretation [102].
The National Comprehensive Cancer Network and American Society of Clinical 
Oncology recommended the use of RS as a manual for adjuvant systemic therapy in 
patients with ER positive, HER2 negative, lymph node-negative invasive BCs that 
are ≥0,5 cm in size [116, 117]. In some studies, the entity of focality was determined 
using histological parameters, while others use clinical and radiographic data only. 
Most authors do not differentiate between MF and MC tumours, and some almost 
universally analyse these groups together [95]. Not all patients underwent the 
same pre-operative radiologic assessment or surgical treatment, which may lead to 
inaccurate classification of the patients as having unifocal carcinomas when they 
actually had an unidentified MF or MC condition [76]. Oncological decisions in 
the systemic adjuvant therapy for BC are based on the histological criterion and 
immunohistochemical profile of the largest tumour focus, ignoring the smaller 
synchronous cancers [118, 119].
Histological characteristics of the metastases (type and grade) of axillary lymph 
nodes in multiple breast cancers correlate with the histological type with an unfa-
vourable prognosis and/or highest histological grade, which may not necessarily 
correspond to the tumour focus of the largest diameter. For this reason, we accen-
tuate the need to individually report on and assess every single tumour focus in 
multiple BCs [8]. A new classification may be required for bilateral BCs that would 
include the size of the tumour in both breasts [120]. TNM staging does not take 
the tumour biology (hormone receptor status, grade, Ki-67, genetic markers) into 
account. Additional studies are required about the advantage of using biomarkers to 
improve the accuracy of staging [51]. Despite the diameter of the largest focus being 
smaller than the volume of the entire tumour, the sum of diameters of all foci will 
be bigger than the actual tumour volume, since volume is proportional to one third 
of the diameter. However, using tumour diameter to assess the size is convenient 
in the sense of being easier to measure [81]. The use of Tsum in clinical practice may 
improve the current staging process and change the approach, in particular for 
patients with early stage of the disease [51].
There are certain limitations of the retrospective view of MF/MC breast cancer 
and information on macroscopic appearance which is no longer available. The status 
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it is not evaluated for all tumour foci, meaning that the morphological nature of the 
MF/MC condition in these patientscannot be reviewed. Tumour characteristics of 
the second largest lesion are usually not tested, since most medical centres do not 
routinely perform immunohistochemical staining of each focus. However, certain 
findings indicate that the biology of the second tumour may affect the prognosis 
[121], which is why it is recommended to assess tumour markers in each multiple 
focus [9]. For instance, if the second lesion was hormone-positive or HER2-positive 
and the main lesion was triple-negative, the chance to administer endocrine therapy 
or molecular targeted therapy may be missed. That being said, there is considerable 
controversy surrounding the assessment of Ki-67 in the literature and, despite the 
efforts to standardise it, a certain degree of subjectivity still remains. Likewise, its 
limit value is not generally accepted [8].
Future studies observing molecular profiles of separate tumour foci in the same 
breast could shed light on this matter and provide clinically relevant information 
for therapy manual-based decisions. Another limitation is the median monitoring 
of under 5 years [95] and the bias of multicentric studies [120]. Failure to factor in 
the heterogeneity of the focus of an additional tumour could prevent the patients 
from taking advantage of appropriate therapies [31, 89, 122]. Most studies are 
retrospective or incidental in nature, which neither compare breast-conserving 
surgery with mastectomy nor analyse locoregional recurrence as a primary goal in 
MSIBC [123].
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